Is Sunshine Biopharma Stock a Good Investment?
Sunshine Biopharma Investment Advice | SBFMW |
- Examine Sunshine Biopharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Sunshine Biopharma's leadership team and their track record. Good management can help Sunshine Biopharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Sunshine Biopharma's business and its evolving consumer preferences.
- Compare Sunshine Biopharma's performance and market position to its competitors. Analyze how Sunshine Biopharma is positioned in terms of product offerings, innovation, and market share.
- Check if Sunshine Biopharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Sunshine Biopharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Sunshine Biopharma Warrant stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Sunshine Biopharma Warrant is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Good | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Sunshine Biopharma Stock
Researching Sunshine Biopharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company recorded a loss per share of 2.21. Sunshine Biopharma had not issued any dividends in recent years.
To determine if Sunshine Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Sunshine Biopharma's research are outlined below:
| Sunshine Biopharma is way too risky over 90 days horizon | |
| Sunshine Biopharma has some characteristics of a very speculative penny stock | |
| Sunshine Biopharma appears to be risky and price may revert if volatility continues | |
| Sunshine Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 24.09 M. Net Loss for the year was (4.51 M) with profit before overhead, payroll, taxes, and interest of 110.6 K. | |
| Sunshine Biopharma Warrant has accumulated about 40.56 M in cash with (8.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.8, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Sunshine Biopharma has a frail financial position based on the latest SEC disclosures |
Sunshine Biopharma Quarterly Accounts Payable |
|
Sunshine Biopharma's profitablity analysis
Sunshine Biopharma's profitability indicators refer to fundamental financial ratios that showcase Sunshine Biopharma's ability to generate income relative to its revenue or operating costs. If, let's say, Sunshine Biopharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Sunshine Biopharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Sunshine Biopharma's profitability requires more research than a typical breakdown of Sunshine Biopharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.17) | (0.18) | |
| Return On Capital Employed | (0.22) | (0.21) | |
| Return On Assets | (0.16) | (0.17) | |
| Return On Equity | (0.21) | (0.20) |
Determining Sunshine Biopharma's profitability involves analyzing its financial statements and using various financial metrics to determine if Sunshine Biopharma is a good buy. For example, gross profit margin measures Sunshine Biopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Sunshine Biopharma's profitability and make more informed investment decisions.
The data published in Sunshine Biopharma's official financial statements usually reflect Sunshine Biopharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Sunshine Biopharma. For example, before you start analyzing numbers published by Sunshine accountants, it's critical to develop an understanding of what Sunshine Biopharma's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Sunshine Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Sunshine Biopharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Sunshine Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Sunshine Biopharma Warrant. Please utilize our Beneish M Score to check the likelihood of Sunshine Biopharma's management manipulating its earnings.
Evaluate Sunshine Biopharma's management efficiency
The company has return on total asset (ROA) of (0.1057) % which means that it has lost $0.1057 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2104) %, meaning that it generated substantial loss on money invested by shareholders. Sunshine Biopharma's management efficiency ratios could be used to measure how well Sunshine Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.18 in 2024. Return On Capital Employed is likely to climb to -0.21 in 2024. At this time, Sunshine Biopharma's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to climb to about 26.1 M in 2024, despite the fact that Non Currrent Assets Other are likely to grow to (1.7 M).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.87 | 0.92 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | 0.81 | 0.85 | |
| Enterprise Value Over EBITDA | (139.12) | (146.07) | |
| Price Book Value Ratio | 31.15 | 29.59 | |
| Enterprise Value Multiple | (139.12) | (146.07) | |
| Price Fair Value | 31.15 | 29.59 | |
| Enterprise Value | 580.5 M | 290.4 M |
The analysis of Sunshine Biopharma's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Sunshine Biopharma's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Sunshine Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta (0.78) |
Basic technical analysis of Sunshine Stock
As of the 15th of May 2024, Sunshine Biopharma has the Semi Deviation of 18.77, risk adjusted performance of 0.0811, and Coefficient Of Variation of 867.59. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sunshine Biopharma, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We have collected data for nineteen technical drivers for Sunshine Biopharma Warrant, which can be compared to its competition. Please validate Sunshine Biopharma variance and potential upside to decide if Sunshine Biopharma is priced more or less accurately, providing market reflects its prevalent price of 0.18 per share. As Sunshine Biopharma appears to be a penny stock we also recommend to double-check its total risk alpha numbers.Sunshine Biopharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sunshine Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sunshine Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sunshine Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Steve Slilaty over a month ago Acquisition by Steve Slilaty of 321305416 shares of Sunshine Biopharma at 0.0026 subject to Rule 16b-3 |
Understand Sunshine Biopharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Sunshine Biopharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0811 | |||
| Market Risk Adjusted Performance | 0.3237 | |||
| Mean Deviation | 17.31 | |||
| Semi Deviation | 18.77 | |||
| Downside Deviation | 23.38 | |||
| Coefficient Of Variation | 867.59 | |||
| Standard Deviation | 23.44 | |||
| Variance | 549.46 | |||
| Information Ratio | 0.1117 | |||
| Jensen Alpha | 2.07 | |||
| Total Risk Alpha | (0.06) | |||
| Sortino Ratio | 0.112 | |||
| Treynor Ratio | 0.3137 | |||
| Maximum Drawdown | 111.11 | |||
| Value At Risk | (33.33) | |||
| Potential Upside | 44.44 | |||
| Downside Variance | 546.49 | |||
| Semi Variance | 352.48 | |||
| Expected Short fall | (23.71) | |||
| Skewness | (0.03) | |||
| Kurtosis | 0.6298 |
| Risk Adjusted Performance | 0.0811 | |||
| Market Risk Adjusted Performance | 0.3237 | |||
| Mean Deviation | 17.31 | |||
| Semi Deviation | 18.77 | |||
| Downside Deviation | 23.38 | |||
| Coefficient Of Variation | 867.59 | |||
| Standard Deviation | 23.44 | |||
| Variance | 549.46 | |||
| Information Ratio | 0.1117 | |||
| Jensen Alpha | 2.07 | |||
| Total Risk Alpha | (0.06) | |||
| Sortino Ratio | 0.112 | |||
| Treynor Ratio | 0.3137 | |||
| Maximum Drawdown | 111.11 | |||
| Value At Risk | (33.33) | |||
| Potential Upside | 44.44 | |||
| Downside Variance | 546.49 | |||
| Semi Variance | 352.48 | |||
| Expected Short fall | (23.71) | |||
| Skewness | (0.03) | |||
| Kurtosis | 0.6298 |
Consider Sunshine Biopharma's intraday indicators
Sunshine Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Sunshine Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | 9.2 T | |||
| Rate Of Daily Change | 1.06 | |||
| Day Median Price | 0.18 | |||
| Day Typical Price | 0.18 | |||
| Price Action Indicator | 0.005 | |||
| Period Momentum Indicator | 0.01 |
Sunshine Stock media impact
Far too much social signal, news, headlines, and media speculation about Sunshine Biopharma that are available to investors today. That information is available publicly through Sunshine media outlets and privately through word of mouth or via Sunshine internal channels. However, regardless of the origin, that massive amount of Sunshine data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Sunshine Biopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Sunshine Biopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Sunshine Biopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Sunshine Biopharma alpha.
Sunshine Biopharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Sunshine Biopharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Sunshine Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Analysis Now
Equity AnalysisResearch over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
| All Next | Launch Module |
Sunshine Biopharma Corporate Executives
Elected by the shareholders, the Sunshine Biopharma's board of directors comprises two types of representatives: Sunshine Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sunshine. The board's role is to monitor Sunshine Biopharma's management team and ensure that shareholders' interests are well served. Sunshine Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sunshine Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Camille Sebaaly | CFO Secretary | Profile |
How to buy Sunshine Stock?
To provide specific investment advice or recommendations on Sunshine Biopharma Warrant stock, we recommend investors consider the following general factors when evaluating Sunshine Biopharma Warrant. This will help you to make an informed decision on whether to include Sunshine Biopharma in one of your diversified portfolios:- Examine Sunshine Biopharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Sunshine Biopharma's leadership team and their track record. Good management can help Sunshine Biopharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Sunshine Biopharma's business and its evolving consumer preferences.
- Compare Sunshine Biopharma's performance and market position to its competitors. Analyze how Sunshine Biopharma is positioned in terms of product offerings, innovation, and market share.
- Check if Sunshine Biopharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Sunshine Biopharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Sunshine Biopharma Warrant stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Sunshine Biopharma Warrant is a good investment.
Already Invested in Sunshine Biopharma Warrant?
The danger of trading Sunshine Biopharma Warrant is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Sunshine Biopharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Sunshine Biopharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Sunshine Biopharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Sunshine Biopharma is a strong investment it is important to analyze Sunshine Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sunshine Biopharma's future performance. For an informed investment choice regarding Sunshine Stock, refer to the following important reports: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma Warrant. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For more information on how to buy Sunshine Stock please use our How to Invest in Sunshine Biopharma guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for Sunshine Stock analysis
When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |
Is Sunshine Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.21) | Revenue Per Share 99.017 | Quarterly Revenue Growth 0.949 | Return On Assets (0.11) | Return On Equity (0.21) |
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Sunshine Biopharma's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.